Genius Sports Limited (GENI) - Due Diligence

hourglass

Loading…

Preparing the latest DD data, styles and content.

63OpportunityDD: Aug 09, 2026Analyst: 67

paidReference price

USD 7.65 (12/08/2026)

domainMkt cap

$2.05B

pie_chartShares

267.63M

candlestick_chart52W

$3.83-$13.73

trending_downShort interest

INFONYSESports Data & Technology2000 employeesFounded 2016

Verdict: Moderately Attractive — Dislocation partially priced

Fallen angel down 45% from 52W high after leveraged Legend acquisition. Q2 2026 blowout (rev +65%, guidance raised) plus fresh Kalshi/Polymarket partnerships trigger 6 analyst PT hikes (Aug 7-8). However the DD-derived fair value (~$10.10) delivers a modest +33% upside vs a symmetric −28% downside: the asymmetric setup implied by the fallen-angel screen does NOT sustain a strict 2.5x asymmetry gate. Attractive on quality of business and multiple gap vs SRAD, but leverage (2x net) and soft floor (asset-light software, no cash cushion) leave meaningful downside if execution misses.

📊 DIANALITICS RESEARCH INDEX Company & Thesis Assessment Score /100 — updated 2026-08-09

Genius Sports Limited (GENI)

Sports Data & Technology · NYSE · London

"Quality asset at leveraged inflection — modest asymmetry, not exceptional"

Secular tailwind Recurring revenue Leveraged 2x No hard floor Multiple gap vs SRAD

Fin. strength

/20 pts

EBITDA/FCF

/15 pts

Debt/leverage

/15 pts

Stage/business

/15 pts

Catalysts

/10 pts

Reg. risk

/8 pts

Risk/reward

/7 pts

Management

/5 pts

Sector/macro

/3 pts

Compliance

/2 pts

💡 Fair Value Estimate — EV/EBITDA (FY27E consolidated, peer-derived)

Fair value base case

USD 10.1

Range: USD 5.50-USD 13.5

Reference price: USD 7.65 (12/08/2026)

Base upside/downside: +32%

Consolidated EV/EBITDA on FY27E (first full Legend year) as primary; peer median 8.7x, GENI at 8.0x reflects leverage discount. Cross-check EV/Revenue at 2.3x aligns with SRAD 2.6x. Weighted FV = 0.20×$13.50 + 0.55×$10.10 + 0.25×$5.50 = $9.63 (below base case: bear scenario meaningfully weighs). Base upside +33% vs bear downside −28% = asymmetry ratio 1.18x — below the 2.5x screening gate, hence the "Moderately Attractive" verdict rather than a strong asymmetric setup. ⚠️ Not investment advice.

Component	Assumption	USD/share
Consolidated EBITDA value	$380M FY27E Adj EBITDA × 8.0x EV/EBITDA / 268M shares	+11.34
Prediction markets option	25% prob × $250M NPV (Kalshi + Polymarket + LatAm) / 268M	+0.23
Cash on balance sheet	~$250M end Q2 2026 (post-Legend closing outflows) / 268M	+0.93
Debt outstanding	−$785M ($825M term loan drawn + revolver, maturity 2031) / 268M	−2.93
Debt paydown FY26E	+$200M FCF applied to debt (mgmt guides 2x net leverage by YE)	+0.75
Earn-out dilution	~6M new shares to Zeal for earn-out at ~$9 = −$54M value / 268M	−0.20
FV base case	Sum of components above	≈ $10.12

Bull

$13.50

Probability: 20%

Legend synergies exceed 15%, FY27 EBITDA reaches $420M, multiple re-rates to 9.5x (halfway to SRAD gap), prediction markets contribute $50M+ EBITDA by 2027. Upside: +78%.

Base

$10.10

Probability: 55%

Guidance delivered, Legend integrates on plan, 2x leverage by YE26, 1.5x by YE27. FY27 EBITDA $380M at 8.0x multiple. Upside: +33%.

Bear

$5.50

Probability: 25%

Sportsbook contract renegotiations pressure margins, Legend integration slips, EBITDA stalls at $310M, multiple compresses to 6.0x on debt overhang. Downside: −28%.

Methodology: Consolidated EV/EBITDA on FY27E (first full Legend year) as primary; peer median 8.7x, GENI at 8.0x reflects leverage discount. Cross-check EV/Revenue at 2.3x aligns with SRAD 2.6x. Weighted FV = 0.20×$13.50 + 0.55×$10.10 + 0.25×$5.50 = $9.63 (below base case: bear scenario meaningfully weighs). Base upside +33% vs bear downside −28% = asymmetry ratio 1.18x — below the 2.5x screening gate, hence the "Moderately Attractive" verdict rather than a strong asymmetric setup. ⚠️ Not investment advice. Not investment advice.

check_circle

✅ Fresh Q2 catalysts — Aug 4-8, 2026

Q2 2026 (Aug 6): revenue $195.5M +65% YoY, adj EBITDA $52.6M +54%, both beat guidance. FY26 revenue guide raised to $1.005B-$1.025B, adj EBITDA raised to $285M-$295M. New partnerships announced Aug 4-5: exclusive data/streaming with Polymarket + Kalshi (prediction markets vertical). Six analyst PT hikes on Aug 7-8: Needham, Oppenheimer, Guggenheim, Roth Capital all raised to $12; Goldman to $10.50; Stifel to $8.50. Wells Fargo lone downgrade to Equal Weight, $8 PT.

Floor caveat: GENI has NO hard asset floor (no net cash, no tangible book of consequence, $535M net debt); the floor is soft — contracted recurring revenue base plus long-term NFL/NBA/MLB rights. This is a key concession vs a "pure" asymmetry setup and is reflected in the bear scenario.

📊 Capital Structure · Short Interest · Buyback & Dilution

🟡 Short Interest

~8-10%

Moderate. Reflects skepticism on Legend synergies delivery + GAAP loss widening in Q2. Days to cover ~4-5. No squeeze setup.

🟡 Share dilution (1Y)

+5.5%

Shares out from ~253M (Aug 2025) to 267.6M today. Legend deal added ~10M shares Apr 2026. Additional 4-6M earn-out shares possible 2027-2028.

🔴 Buyback

No buyback program. Capital allocation prioritizes debt paydown (2x → 1.5x leverage target 2027) and Legend integration capex.

Short Interest — context

GENI — 9%

Interpretation: moderate short interest reflects genuine debate on execution risk (Legend integration, prediction market TAM) rather than a directional short thesis. No known coordinated short-seller report. Insider selling normal-course (Form 4s show routine 10b5-1 sales, no cluster >$500K in trailing 90 days). No lead-plaintiff class action deadlines known.

$Financial analysis — FY 2026E

Revenue TTM

$790M

+41.5% YoY

Adj EBITDA FY26E

$290M

+38% vs FY25

Net debt (est. YE26)

$535M

~1.85x EBITDA

FCF conversion H2 26

~50%

Reduced by interest

Item	FY2023	FY2024	FY2025	FY2026E	Guidance 2026
Revenue ($M)	413	511	669	~1,015	$1,005-1,025M
Adj EBITDA ($M)	60	121	210	~290	$285-295M
Adj EBITDA margin	14.5%	23.7%	31.4%	28.6%	—
Net income ($M)	−96	−63	−112	~−175	Legend costs weigh
Cash & equiv ($M)	117	142	210	~250	Post-M&A
Total debt ($M)	18	14	12	~785	Legend financing

Adj EBITDA is the market-followed metric; GAAP loss widens FY26 primarily due to Legend deal transaction costs, interest expense on new $825M term loan, and amortization of acquired intangibles. Underlying operating momentum is strong (organic +45% Q2).

Quarterly dynamics — last 5 quarters
Metric	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue ($M)	118.8	144.5	217.8	168.5	195.5
Adj EBITDA margin	28.7%	28.4%	34.2%	25.8%	26.9%
Net loss ($M)	−28.5	−14.8	−22.1	−45.2	−76.7
End-of-period cash ($M)	168	178	210	223	~250

Financial position and sustainability

Adj EBITDA margin FY26E

28.6%

Net leverage YE26E

1.85x

Revenue retention (est.)

>90%

EV/EBITDA fw discount vs SRAD

−43%

account_tree

Business model — sports data infrastructure & media

Three-pillar B2B model post-Legend

Genius Sports collects, packages and distributes real-time sports data + video for leagues (NFL, NBA, MLB, EPL, FIBA) and monetizes it via sportsbooks, media and — post-Legend — affiliate media networks. Legend acquisition (Apr 2026, $1.2B) added a top-3 sports/gaming affiliate marketing business. Recent partnerships with Kalshi (Aug 5) and Polymarket (Aug 4) open a fourth vertical: prediction markets, where GENI is positioned as the neutral official data provider — a structurally advantaged position vs pure operators like DKNG.

Betting Technology, Content & Services ~$620M FY26E (~61% rev) 🟢 ramping Official data + streaming to sportsbooks; NFL exclusive is anchor. Long-term contracts, ~90%+ retention. Main risk: sportsbook consolidation compresses take rate. Media & Affiliate (Legend + core) ~$310M FY26E (~30% rev) 🟢 ramping Legend affiliate network + GENI programmatic. Grew 65% Q2 (Legend consolidation). GM ~40%. Cross-sell to sportsbook customers is synergy driver. Execution risk on integration. Sports Technology & Prediction Mkts ~$85M FY26E (~9% rev) 🟡 to prove League-facing technology (SaaS) + new Kalshi/Polymarket data-feeds. Prediction markets is small revenue now but high-optionality TAM if CFTC framework matures.

gavel

Legal, regulatory and risk analysis

Leverage & interest burden

High

New $785M debt lifts net leverage from ~net cash to ~1.85x YE26E. Interest expense cuts FCF conversion to 50% in H2 26. Cash flow becomes highly sensitive to EBITDA delivery.

Legend integration execution

Moderate

$1.2B acquisition closed Apr 30, 2026. Full synergy realization is 2027-2028 story. Affiliate marketing is culturally different from B2B tech data — retention of Legend leadership and clients critical.

Sportsbook customer concentration

Moderate

Top-5 sportsbook customers likely >45% of B2B revenue. Consolidation (e.g. Fanatics/PointsBet) or renegotiation of take-rate on renewals could compress ARPU.

NFL contract renewal risk

High

The exclusive NFL data deal (through 2028) is the crown jewel. Loss or unfavorable renewal would materially compress the moat and multiple.

Prediction markets regulatory

Moderate

Kalshi/Polymarket sports contracts operate under CFTC framework; state gaming regulators have challenged. Adverse ruling would nullify a growing option value line.

Recurring revenue moat

Positive

~90%+ retention on multi-year data-rights contracts creates predictable revenue and provides operational floor absent hard asset floor.

Secular sports betting tailwind

Positive

US sports betting handle continues +15-20% CAGR through 2027; prediction markets emerging as +$5B TAM by 2028. GENI is picks-and-shovels play, not directional bet on operator.

Multiple gap vs SRAD

Low

43% EV/EBITDA discount to Sportradar (10.7x vs GENI 4.5x fwd) with faster EBITDA growth. Provides mean-reversion upside if leverage narrative resolves.

article

SWOT analysis

Strengths

+Exclusive NFL data rights through 2028 — highest-value single contract in sports data
+>90% revenue retention on multi-year contracts creates operational floor
+Growing Adj EBITDA base ($60M FY23 → $290M FY26E), operating leverage still emerging
+Neutral position (data provider) advantages GENI in prediction markets vs operators

Weaknesses

−GAAP net loss persistent despite growing Adj EBITDA — high non-cash charges + interest
−Post-Legend leverage 2x + limited FCF conversion in H2 26 constrains flexibility
−Legend acquisition dilutes shareholders ~4% + earn-out overhang
−No hard asset floor; asset-light software business — bear case is meaningful

Opportunities

→Multiple re-rating: 43% discount to SRAD despite higher growth is significant catch-up upside
→Prediction markets vertical (Kalshi, Polymarket, others) — call option on nascent TAM
→Legend cross-sell to existing sportsbook customer base creates revenue synergies
→EU / LatAm expansion with regulated markets opening (Brazil live betting Q4 2026)

Threats

!Sportsbook consolidation (Fanatics-M&A) could compress data take-rates on renewal
!Loss of NFL exclusivity on 2028 renewal would collapse the primary moat
!CFTC ruling against Kalshi sports contracts kills prediction markets option
!Higher-for-longer rates keep debt-servicing costs elevated and multiple compressed

article

Summary by assessment area

🟡 Financial risk — Moderate

Leverage 1.85x YE26E is manageable but new vs historical net cash position
FCF conversion halved in H2 26 by interest burden
Path to 1.5x by YE27 credible if EBITDA delivers

🔵 Valuation — Moderately attractive

FV base $10.10 vs price $7.59 = +33% upside
Bear case $5.50 = −28% downside — asymmetry only 1.18x
Consensus $10.83 (+43%) close to base case

🟢 Business quality — Strong

Anchor NFL contract + >90% retention
Secular tailwind + neutral position vs operators
Guidance raised, catalysts stacked short-term

{ "verdict_label": {"it": "Moderatamente Attraente — Asimmetria parziale", "en": "Moderately Attractive — Partial asymmetry"}, "verdict_text": {"it": "Fallen angel −45% dal massimo dopo l'acquisizione Legend leveraged. Q2 2026 forte (rev +65%, guidance alzata) e nuove partnership Kalshi/Polymarket. FV DD $10.10 = +33% upside vs −28% downside bear: asimmetria 1.18x, sotto la soglia 2.5x. Business di qualità con gap multiplo vs SRAD, ma leva 2x e assenza di floor duro limitano il caso investimento.", "en": "Fallen angel −45% from 52W high after leveraged Legend acquisition. Q2 2026 blowout (rev +65%, guidance raised) plus Kalshi/Polymarket partnerships. DD-derived FV $10.10 = +33% upside vs −28% bear downside: asymmetry ratio 1.18x, below the 2.5x screening gate. Quality business with 43% multiple discount vs SRAD, but 2x leverage and absence of hard floor cap the investment case."}, "bull_points": [ {"it": "Guidance FY26 alzata + 6 rialzi target price analisti Aug 7-8", "en": "FY26 guidance raised + 6 analyst PT hikes on Aug 7-8"}, {"it": "43% sconto EV/EBITDA vs Sportradar con crescita EBITDA più alta", "en": "43% EV/EBITDA discount vs Sportradar with faster EBITDA growth"}, {"it": "Contratto NFL esclusivo + retention >90% = floor operativo forte", "en": "Exclusive NFL contract + >90% retention = strong operational floor"} ], "bear_points": [ {"it": "Leva netta 1.85x YE26E, FCF conversion dimezzato H2 26", "en": "Net leverage 1.85x YE26E, FCF conversion halved in H2 26"}, {"it": "Nessun floor duro (no cash netta, no tangible book significativo)", "en": "No hard floor (no net cash, no meaningful tangible book)"}, {"it": "Asimmetria upside/downside 1.18x — sotto soglia 2.5x screening", "en": "Upside/downside asymmetry 1.18x — below 2.5x screening gate"} ], "risks": [ {"it": "Rinnovo NFL 2028 — perdita esclusiva compromette moat", "en": "NFL 2028 renewal — loss of exclusivity breaks the moat"}, {"it": "Concentrazione sportsbook top-5 >45% dei ricavi B2B", "en": "Top-5 sportsbook customer concentration >45% of B2B revenue"}, {"it": "Ruling CFTC contrario su Kalshi elimina option prediction markets", "en": "Adverse CFTC ruling on Kalshi nullifies prediction markets option"} ] }

Sources & Disclaimer

Sources: Stock Analysis (real-time GENI quote), TipRanks (analyst PT hikes Aug 7-8, 2026), Business Wire (Q2 2026 earnings release Aug 6), Investing.com (Q2 2026 slides), CNBC (Q2 recap), Simply Wall St (valuation narratives), SEC 6-K filings (Legend acquisition financing), Multiples.vc / Investing.com (SRAD peer comparables). Market data — last verified close 2026-08-07: GENI $7.59, market cap $2.03B, 52W range $3.83–$13.73, shares outstanding 267.63M. Short interest ~9% (approx.). This document is for informational purposes only and does not constitute financial or investment advice.